Initiating statin therapy soon after a type 2 diabetes diagnosis could protect the heart and might be linked to a reduced dementia risk. A significant study presented at the European Society of Cardiology Congress in Munich on August 30 revealed that adults who started taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over a decade compared to those who delayed treatment for up to five years.
The study, published in The Lancet Regional Health – Europe, also showed that those who waited one to five years to start statin therapy still had a 10% lower relative risk of dementia. Statins are medications prescribed to reduce ‘bad’ LDL cholesterol and help lower the risk of heart attacks and strokes.
Researchers analyzed health data from 132,585 patients in Denmark, all diagnosed with type 2 diabetes between 2006 and 2019 without prior statin use or dementia history. Over a median follow-up of 7.1 years, they examined the impact of statin timing on dementia rates.
Dr. Liron Sinvani, a geriatrician and director for research and innovation at the Northwell Institute for Healthy Aging in New York, acknowledged this as a substantial observational study adding to the evidence that statins might support brain health. Although a 15% reduction is modest, it is considered significant.
Older adults with type 2 diabetes face an increased risk of cognitive decline and heart disease. Statin initiation within one year of diagnosis was linked to a 15% lower risk of developing dementia, while delaying therapy reduced the benefit to 10%.
Despite guidelines recommending statins for many adults aged 40 to 75 with diabetes, therapy is not always started soon after a diabetes diagnosis. The study further explored timing’s effect on dementia risk. Those beginning statin use within a year of diagnosis had a lower risk than those who delayed.
“The message here is that maybe waiting is actually not the right approach,” Sinvani said, suggesting earlier statin consideration in diabetes care.
She found the results particularly noteworthy as the benefit stemmed from a lowered risk of vascular dementia, not Alzheimer’s disease. Statins lower cholesterol, reduce inflammation, and protect blood vessels, which may prevent vascular damage in the brain.
Statins should complement a comprehensive health strategy, incorporating regular exercise, a healthy diet, and social engagement. Being an observational study, the findings indicate a strong association but do not confirm a causal relationship.
Nearly half of dementia cases could be preventable or delayed by addressing modifiable risk factors, suggests the Lancet Commission. However, because the study lacked a randomized clinical trial structure, researchers could not definitively claim that statins prevent dementia.
Dr. Sinvani urged type 2 diabetes patients not taking statins to consult their doctors on the medication’s suitability. This research represents a meaningful step in understanding statins’ potential in dementia prevention.